Four triplets and one quadruplet in EGFR were found at a frequency of 0.3% (5/1627) of lung cancers with mutations prior to treatment with tyrosine kinase inhibitor (TKI) (Table 4). The gene discussed is EGFR; the disease is lung cancer.